Inclusion Criteria:

          -  Participants with advanced, nonresectable, or recurrent solid tumor for which no
             alternative standard therapy or no effective therapy exists

          -  Expansion-part 1 only: breast cancer with confirmed diagnosis, human epidermal growth
             factor (HER2) negative (immunohistochemistry [IHC] 0/1+, or fluorescence in situ
             hybridization [FISH] negative), prior chemotherapy of anthracycline and taxane (unless
             contraindicated), and up to 3 prior chemotherapy regimens to advanced or metastatic
             disease

          -  Expansion-part 2 only: nonresectable ACC with confirmed diagnosis and one or more
             prior chemotherapy regimens (unless contraindicated) Expansion-part 3, 4 and 5 only:
             nonresectable GC, EGC and SCLC with confirmed diagnosis and 2 or more prior
             chemotherapy regimens (unless contraindicated) (1 or more prior chemotherapy regimens
             for EGC participant who received combination therapy of platinum and taxane).

          -  Life expectancy of ≥ 12 weeks

          -  Eastern Cooperative Oncology Group-Performance Status (ECOG-PS) of 0 to 1

          -  Japanese participants aged ≥ 20 years at the time of informed consent

          -  All adverse events (AEs) due to previous anti-cancer therapy have either returned to
             Grade 0 or 1 except for alopecia and Grade 2 peripheral neuropathy

          -  Adequate washout period before study drug administration:

               -  Chemotherapy, hormonal therapy and radiotherapy: 3 weeks or more

               -  Any therapy with antibody: 4 weeks or more

               -  Any investigational drug or device: 4 weeks or more

               -  Blood/platelet transfusion or granulocyte-colony stimulating factor (G-CSF): 2
                  weeks or more

          -  Adequate renal function defined as serum creatinine < 2.0 milligrams per deciliter
             (mg/dL) or creatinine clearance ≥ 40 milliliters per minute (mL/min) per the Cockcroft
             and Gault formula

          -  Adequate bone marrow function:

               -  Absolute neutrophil count (ANC) ≥ 2,000/millimeters cubed (mm^3) (≥ 2.0 ×
                  10^3/microliter [µl])

               -  Platelets ≥ 100,000/mm^3 (≥ 100 × 10^9/Liter [L])

               -  Hemoglobin ≥ 9.0 grams (g)/dL (Expansion-part only: ≥ 8.5 g/dL)

          -  Adequate liver function:

               -  Adequate blood coagulation function as evidenced by an International Normalized
                  Ratio (INR) ≤ 1.5

               -  Total bilirubin ≤ 1.5 × upper limit of normal (ULN) except for unconjugated
                  hyperbilirubinemia or Gilbert's syndrome

               -  Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate
                  aminotransferase (AST) ≤ 3 × ULN

          -  Expansion-part only: At least one measurable lesion based on Response Evaluation
             Criteria in Solid Tumors (RECIST) 1.1

          -  Willing and able to give informed consent and comply with all aspects of the protocol

        Exclusion Criteria:

          -  Any of cardiac conditions as follows:

               -  Heart failure New York Heart Association (NYHA) Class II or above

               -  Unstable ischaemic heart disease (myocardial infarction within 6 months prior to
                  starting study drug, or angina requiring use of nitrates more than once weekly)

               -  Prolongation of Fridericia's corrected QT (QTcF) interval to > 480 milliseconds
                  (msec)

          -  History of hypersensitivity reaction by liposomal formulation agent

          -  Major surgery within 21 days prior to starting study drug

          -  Previous treatment with eribulin

          -  Previous radiation therapy encompassing an extensive region including the bone marrow
             (e.g. > 30% of bone marrow)

          -  Known intolerance to the study drug or any of the excipients

          -  Known to be human immunodeficiency virus (HIV) positive

          -  Active viral hepatitis (B or C) as demonstrated by positive serology or requiring
             treatment

          -  Diagnosed with meningeal carcinomatosis

          -  Participants with brain or subdural metastases or invasion are not eligible, unless
             they have completed local therapy and have discontinued the use of corticosteroids for
             this indication for at least 4 weeks before starting treatment in this study. Any
             signs (e.g. radiologic) or symptoms of brain metastases must be stable for at least 4
             weeks before starting study treatment.

          -  Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring
             active treatment, including the use of oxygen.

          -  Expansion-part only: history of active malignancy (except for primary tumor, or
             definitively treated melanoma in-situ, basal or squamous cell carcinoma of the skin,
             carcinoma in-situ of the bladder or cervix, or early stage gastric/colorectal cancer)
             within the past 24 months prior to the first dose of study drug

          -  Evidence of clinically significant disease/status (e.g. cardiac, respiratory,
             gastrointestinal, renal disease) that in the opinion of the investigator(s) could
             affect the participant's safety or interfere with the study assessments

          -  Females who are breastfeeding or pregnant at Screening or Baseline (as documented by a
             positive beta-human chorionic gonadotropin [β-hCG] or hCG test). A separate baseline
             assessment is required if a negative screening pregnancy test was obtained more than
             72 hours before the first dose of study drug.

          -  Males with impregnate potential or females of childbearing potential who or whose
             partner do not agree with medically effective method of contraception throughout the
             entire study period and for 28 days (90 days for male) after study drug
             discontinuation